The great success of targeted therapy with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI): gefitinib and erlotinib, for treatment of lung adenocarcinoma has made targeted therapy become the most popular modality for major human cancers [3–7]. This evidence concerns the gene EGFR and cancer.